EL MICROAMBIENTE TUMORAL COMO DIANA PARA EL DESARROLLO DE INMUNOTERAPIAS CAR-T EN TUMORES SOLIDOS
PID2019-108989RB-I00
•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento Científico y Tecnológico del Sistema de I+D+i
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos I+D
Año convocatoria 2019
Unidad de gestión Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020
Centro beneficiario FUNDACION PARA LA INVESTIGACION MEDICA APLICADA
Identificador persistente http://dx.doi.org/10.13039/501100011033
Publicaciones
Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)
Encontrada(s) 1 página(s)
Immune profiling uncovers memory T-cell responses with a Th17 signature in cancer patients with previous SARS-CoV-2 infection followed by mRNA vaccination
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
- Echaide Górriz, Míriam
- Labiano, Ibone
- Delgado, Marina
- Fernández de Lascoiti, Ángela
- Ochoa, Patricia
- Garnica, Maider
- Ramos, Pablo
- Chocarro de Erauso, Luisa
- Fernández Rubio, Leticia
- Arasanz Esteban, Hugo
- Bocanegra Gondán, Ana Isabel
- Blanco, Ester
- Piñeiro Hermida, Sergio
- Morente Sancho, Pilar
- Vera García, Ruth
- Alsina, María
- Escors Murugarren, David
- Kochan, Grazyna
It is unclear whether patients with cancer present inherently impaired responses to COVID-19 and vaccination due to their treatments, neoplastic diseases or both. To address this question, immune profiling was performed in three cohorts of healthy donors and oncologic patients: infected with SARS-CoV-2, BNT162b2-vaccinated, and with previous COVID-19 disease and subsequently vaccinated. Cancer patients showed good antibody responses to vaccination, but poor induction of T-cell responses towards the S protein when compared to infection. Following natural infection, the major targets for T-cells were the SARS-CoV-2 structural proteins M and S, but not the N protein. Similar to antibody titers, the T-cell responses quickly decayed after six months post-vaccination. Significant memory T-cell expansion was observed in vaccinated donors only if previously diagnosed with COVID-19 before undergoing vaccination. Oncologic patients with previous COVID-19 followed by vaccination exhibited potent IL-17+ CD4 and CD8 T-cell responses and elevated numbers of circulating neutrophils in peripheral blood. © 2022 by the authors., The OncoImmunology group is funded by the Spanish Association against Cancer (AECC,
PROYE16001ESCO); Instituto de Salud Carlos III (ISCIII)-FEDER project grants (FIS PI17/02119,
FIS PI20/00010, COV20/00000, and TRANSPOCART ICI19/00069); a Biomedicine Project grant
from the Department of Health of the Government of Navarre (BMED 050-2019); Strategic projects
from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013;
LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); Ministerio de
Ciencia e Innovación (PID2019-108989RB-I00, PLEC2021-008094 MCIN/AEI/10.13039/501100011033).
This project received funding from the European Union’s Horizon 2020 Research and Innovation
Programme under grant agreement No. 848166.
PROYE16001ESCO); Instituto de Salud Carlos III (ISCIII)-FEDER project grants (FIS PI17/02119,
FIS PI20/00010, COV20/00000, and TRANSPOCART ICI19/00069); a Biomedicine Project grant
from the Department of Health of the Government of Navarre (BMED 050-2019); Strategic projects
from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013;
LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); Ministerio de
Ciencia e Innovación (PID2019-108989RB-I00, PLEC2021-008094 MCIN/AEI/10.13039/501100011033).
This project received funding from the European Union’s Horizon 2020 Research and Innovation
Programme under grant agreement No. 848166.